Managing Director – Novartis Venture Funds
Dr. Florent Gros is a Managing Director of the Novartis Venture Funds in Basel, Switzerland. He held various senior positions in the intellectual property at Nestlé, Pasteur Mérieux Connaught and Novartis. Since 2006 Florent joined the Novartis Venture Funds. Florent currently serves on the boards of Adicet (US), Anokion (CH), Atlas Genetics (UK), Kanyos (US), Inflazome (IE) and Opsona (IE). His prior investments resulted to the following successful acquisition and IPO listings: Altimmune, Evolva, Gensight, Merus, Neovacs, Okairos and Tigenix. Florent is a Kaufmann Fellow (class 12), he holds a Biotechnology Engineering Master Degree in France. He also holds European and French patent lawyer degrees, and a Master Degree in Private Law.
Head Roche Venture Fund
Carole Nuechterlein has headed the Roche Venture Fund since 2001. Prior to her current position, she worked in the pharmaceutical/biotech industry as an attorney for ten years. She joined Roche from SangStat in Fremont California where she was General Counsel.
She currently serves as a director at CiVi Biopharma, Lumos Pharma, Lysosomal Therapeutics, Inc., Millendo Therapeutics, Mission Therapeutics, Second Genome, Tioma Therapeutics and Vivet Therapeutics and as board observer on Allakos, C4 and Maculogix. Carole also led the investments on Alios, Ambit, AveXis, Conatus, Envoy & Pharmasset. She has a BA from Valparaiso University and a JD from University of Michigan.
More information on the Roche Roche Venture Fund can be found at www.venturefund.roche.com
Partner - HealthCap
Dr. Mårten Steen. Partner of HealthCap. Previously, he has worked with business development at Merck Serono focusing on both product and technology licensing. Mårten is a Medical Doctor trained at Lund University. He has pursued research in the field of protein chemistry and coagulation at Lund University and Novo Nordisk, rendering him a PhD in Clinical Chemistry in 2003. He is the author of 16 scientific papers and published in peer-reviewed journals. He has also a B.Sc. degree in Business Administration from the Lund University School of Economics and Management.
Founder and Managing Partner of Columbus Venture Partners
Founder and Managing Partner of Columbus Venture Partners S.G.E.I.C., S.A
Javier Garcia has spent almost 30 years working in healthcare and the biopharmaceutical industry. He spent 25 years at Eli Lilly and Company. He hold senior management positions in Business Development and Information Technology. Currently he serves on the Board of Artax Biopharma, Bioncotech Therapeutics and PTS. He is also a board member for the National Alliance for Hispanic Health and the Healthy Americas Foundation both NFP organizations in Washington DC.
Mr. Garcia received a Bachelor in Mathematics (Statistics and Operations Research) from Universidad Complutense of Madrid and a MBA from ICADE (Spain).
Managing Partner - Kurma
Scientist by training, Vanessa started joined the Paris based VC fund CDC-Innovation in 1998 as an analyst, prior to joining a California based start up to be in charge of the business development activities. Vanessa then joined Ipsen in 2003, as Strategic Advisor to the CEO and headed the portfolio management team for the gastro-enterology product range (totaling more than 130M€). Vanessa was appointed in 2005 as Product Manager and Team Leader for febuxostat (Adenuric), which received EMA approval in 2008. Vanessa was then successively appointed as Senior Director, Business Development Oncology in 2009 and VP, R&D Strategic Planning in 2011. Vanessa graduated in Biology at Ecole Normale Superieure, Cachan and in Immunology at Pasteur Institute. Vanessa joined Kurma in September 2013 and is responsible for the investment in Xeltis (Switzerland).
General Partner - Ysios Capital
Dr Karen Wagner is a senior executive and entrepreneur with close to 20 years experience in the biopharmaceutical industry. Karen is General Partner at Ysios Capital Partners and her main role at Ysios is to identify and manage therapeutic investments.
Prior to joining Ysios in 2008, Karen was a Global Alliance Director for F. Hoffmann-La Roche in Basel, Switzerland. Among other transactions, she was project leader for the Alnylam-Roche collaboration announced in July 2007, valued at over $1 billion and one of Allicense’s Key Deals of the year. She joined Roche from GLYCART, a biotech company in the antibody engineering space, where she was head of business development. GLYCART was acquired by Roche in 2005 for 235 million Swiss Francs. Karen has also worked as a consultant and was a member of McKinsey & Company’s Global Healthcare Practice.
In addition to Vivet, Karen serves as Chair on the Board of Aelix Therapeutics and is observer on the Boards of Minoryx Therapeutics and Kala Pharmaceuticals. Formerly, she was board member at Cardoz.
She holds a master’s degree in Molecular Biology and a PhD in Cell Biology, both from the University of Konstanz, Germany.
With €8 billion under management, Idinvest Partners is a leading pan-European private equity firm focused on the mid-market segment. Idinvest Partners has developed several complementary areas of expertise including investments in innovative European start-ups, primary, secondary and mezzanine investments in unlisted European companies, and private equity consulting. Founded under the name AGF Private Equity in 1997, Idinvest Partners was formerly part of Allianz until 2010 when it became an independent firm